Search

Your search keyword '"Ginsburg, Elizabeth S."' showing total 336 results
Start Over Author "Ginsburg, Elizabeth S." Publication Type Academic Journals
336 results on '"Ginsburg, Elizabeth S."'

13. Assisted reproductive technology use and outcomes in childhood cancer survivors.

Author

Keefe, Kimberly W., Lanes, Andrea, Stratton, Kayla, Green, Daniel M., Chow, Eric J., Oeffinger, Kevin C., Barton, Sara, Diller, Lisa, Yasui, Yutaka, Leisenring, Wendy M., Armstrong, Gregory T., and Ginsburg, Elizabeth S.

Subjects
REPRODUCTIVE technology, CHILDHOOD cancer, CANCER survivors, INDUCED ovulation, OVARIAN reserve, MENSTRUAL cycle
Abstract

Background: Treatment exposures for childhood cancer reduce ovarian reserve. However, the success of assisted reproductive technology (ART) among female survivors is not well established. Methods: Five‐year survivors of childhood cancer in the Childhood Cancer Survivor Study were linked to the Society for Assisted Reproductive Technology Clinic Outcome Reporting System, which captures national ART outcomes. The authors assessed the live birth rate, the relative risk (RR) with 95% confidence intervals (95% CIs), and associations with treatment exposure using generalized estimating equations to account for multiple ovarian stimulations per individual. Siblings from a random sample of survivors were recruited to serve as a comparison group. Results: Among 9885 female survivors, 137 (1.4%; median age at diagnosis, 10 years [range, 0–20 years]; median years of follow‐up after age 18 years, 11 years [range, 2–11 years]) underwent 224 ovarian stimulations using autologous or donor eggs and/or gestational carriers (157 autologous ovarian stimulation cycles, 67 donor ovarian stimulation cycles). In siblings, 33 (1.4%) underwent 51 autologous or donor ovarian stimulations. Of those who used embryos from autologous eggs without using gestational carriers, 97 survivors underwent 155 stimulations, resulting in 49 live births, for a 31.6% chance of live birth per ovarian stimulation (vs. 38.3% for siblings; p =.39) and a 43.9% chance of live birth per transfer (vs. 50.0%; p =.33). Prior treatment with cranial radiation therapy (RR, 0.44; 95% CI, 0.20–0.97) and pelvic radiation therapy (RR, 0.33; 95% CI, 0.15–0.73) resulted in a reduced chance of live birth compared with siblings. The likelihood of live birth after ART treatment in survivors was not affected by alkylator exposure (cyclophosphamide‐equivalent dose, ≥8000 mg/m2 vs. none; RR, 1.04; 95% CI, 0.52–2.05). Conclusions: Childhood cancer survivors are as likely to undergo treatment using ART as sibling controls. The success of ART treatment was not reduced after alkylator exposure. The results from the current study provide needed guidance on the use of ART in this population. Linking the Childhood Cancer Survivor Study database to the Society for Assisted Reproductive Technology Clinic Outcome Reporting System revealed that childhood cancer survivors are as likely to undergo treatment with assisted reproductive technology as their siblings. The success of assisted reproductive technology was not reduced after alkylator exposure. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Use of preimplantation genetic testing for monogenic disorders and subsequent prenatal care and diagnostic testing.

Author

Bunnell, Megan E., Dobson, Lori J., Lanes, Andrea, and Ginsburg, Elizabeth S.

Abstract

Objective: The goal of preimplantation genetic testing for monogenic or single gene defects (PGT‐M) is to identify inherited pathogenic variants in the embryo prior to embryo transfer, increasing the likelihood of an unaffected child. Prenatal diagnostic testing is recommended to confirm the results of PGT‐M. The purpose of this study was to characterize the population undergoing PGT‐M over time. Methods: This retrospective study examined patients who had a positive pregnancy test after PGT‐M from 2012 to 2019. A query of the internal assisted reproductive technology database and chart review were used. Results: One hundred and 42 patients completed IVF cycles for PGT‐M during this time period and progressed past 10 weeks gestation. There were more PGT‐M cycles over time with 46 cycles between 2012 and 2015 and 96 cycles between 2016 and 2019. Patients varied on the decision to pursue prenatal diagnostic testing after PGT‐M. For those with known follow‐up (130/142), 16 patients underwent diagnostic testing (12%) and 114 did not. Conclusion: As PGT‐M is increasingly utilized prior to pregnancy, it is important for genetic counselors and OB/GYNs to understand the characteristics and outcomes of the population of patients undergoing PGT‐M, including how to counsel about the residual risk of an affected pregnancy after PGT‐M. Key points: What is already known about this topic? PGT‐M is used to identify inherited pathogenic variants in the embryo prior to embryo transfer, increasing the likelihood of an unaffected child.Indications for PGT‐M have traditionally included childhood lethal or childhood onset conditions.Prenatal diagnostic testing is recommended after PGT‐M to confirm the results of the embryo biopsy. What does this study add? Most individuals undergoing PGT‐M are not pursuing diagnostic prenatal testing.There are certain factors about an individual and their pregnancy history that make someone more likely to pursue prenatal diagnostic testing after PGT‐M.The indications for PGT‐M are becoming broader encompassing, in some cases, adult‐onset conditions. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

42. The implementation of an Assisted Reproductive Technologies Ethics Committee (ARTEC).

Author

Ginsburg, Elizabeth S.

Subjects
Human reproductive technology -- Laws, regulations and rules, Bioethics -- Laws, regulations and rules, Ethics committees -- Laws, regulations and rules, Government regulation
Abstract

I. INTRODUCTION The science of assisted reproductive technologies often evolves more rapidly than social acceptance for the treatments developed. This can lead to ethical dilemmas for the health care team, [...]

Published
2005

49. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy

Author

Shifren, Jan L., Braunstein, Glenn D., Simon, James A., Casson, Peter R., Buster, John E., Redmond, Geoffrey P., Burki, Regula E., Ginsburg, Elizabeth S., Rosen, Raymond C., Leiblum, Sandra R., Caramelli, Kim E., and Mazer, Norman A.

Subjects
Sexual disorders -- Drug therapy, Testosterone -- Health aspects
Abstract

A testosterone patch may benefit some women with impaired sexual function, according to a study of 75 women who had their ovaries removed before menopause. The ovaries produce testosterone naturally, and many women who have them removed have impaired sexual function even when treated with estrogen.

Published
2000

Catalog

Books, media, physical & digital resources
See catalog results